The Transforming Growth Factor-Beta (TGF-β) inhibitor Smad7 is an important negative modulator that regulates the strength of TGF-β signaling [144] and it is upregulated in peripheral CD4+ T cells from patients with MS during disease relapse, but not during remission. This evidence concerns the gene CD4 and myeloid sarcoma.